Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析

◆英語タイトル:Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1673
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Amicus Therapeutics Inc (FOLD) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company’s lead product, Migalastat HCl, a small molecule is indicated for the treatment of Fabry disease. The other development products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; Migalastat for other conditions; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Cranbury, New Jersey, the US.

Amicus Therapeutics Inc Key Recent Developments

Mar 23,2020 Amicus Therapeutics confirms business continuity, 2020 strategic priorities and announces proactive efforts to support public health initiatives, patients & employees
Mar 20,2020 Amicus opens gene therapy center focused on Rett Syndrome, Other Rare Diseases
Mar 05,2020 Amicus opens new global research and gene therapy center of excellence in Philadelphia
Mar 02,2020 Amicus Therapeutics announces full-year 2019 financial results and 2020 corporate updates

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Amicus Therapeutics Inc – Key Facts
Amicus Therapeutics Inc – Key Employees
Amicus Therapeutics Inc – Key Employee Biographies
Amicus Therapeutics Inc – Major Products and Services
Amicus Therapeutics Inc – History
Amicus Therapeutics Inc – Company Statement
Amicus Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Amicus Therapeutics Inc – Business Description
Geographical Segment: Ex-US
Performance
Geographical Segment: The US
Performance
R&D Overview
Amicus Therapeutics Inc – Corporate Strategy
Amicus Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Amicus Therapeutics Inc – Strengths
Amicus Therapeutics Inc – Weaknesses
Amicus Therapeutics Inc – Opportunities
Amicus Therapeutics Inc – Threats
Amicus Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Amicus Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 23, 2020: Amicus Therapeutics confirms business continuity, 2020 strategic priorities and announces proactive efforts to support public health initiatives, patients & employees
Mar 20, 2020: Amicus opens gene therapy center focused on Rett Syndrome, Other Rare Diseases
Mar 05, 2020: Amicus opens new global research and gene therapy center of excellence in Philadelphia
Mar 02, 2020: Amicus Therapeutics announces full-year 2019 financial results and 2020 corporate updates
Feb 07, 2020: AmicusTherapeutics announces presentations and posters at 16th Annual WORLDSymposium 2020
Feb 07, 2020: Amicus Therapeutics announces presentations and posters at 16th Annual WORLDSymposium 2020
Jan 13, 2020: Amicus Therapeutics provides full-year 2020 strategic outlook and financial guidance
Jan 09, 2020: Amicus Therapeutics announces preliminary 2019 Galafold revenue – exceeding upper end of prior guidance
Nov 11, 2019: Amicus Therapeutics announces third quarter 2019 financial results and corporate updates
Oct 10, 2019: Amicus Therapeutics announces preliminary third quarter 2019 revenue and financial outlook at 2019 analyst day
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Amicus Therapeutics Inc, Key Facts
Amicus Therapeutics Inc, Key Employees
Amicus Therapeutics Inc, Key Employee Biographies
Amicus Therapeutics Inc, Major Products and Services
Amicus Therapeutics Inc, History
Amicus Therapeutics Inc, Other Locations
Amicus Therapeutics Inc, Subsidiaries
Amicus Therapeutics Inc, Key Competitors
Amicus Therapeutics Inc, Ratios based on current share price
Amicus Therapeutics Inc, Annual Ratios
Amicus Therapeutics Inc, Annual Ratios (Cont...1)
Amicus Therapeutics Inc, Interim Ratios
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Amicus Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Amicus Therapeutics Inc, Performance Chart (2015 - 2019)
Amicus Therapeutics Inc, Ratio Charts
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Laboratorio Teuto Brasileiro SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratorio Teuto Brasileiro SA (Teuto), a subsidiary of Pfizer Inc is a drug company that develops, manufactures, and markets generic and over the counter products. The company’s products include aerodini aerosol salbutamol sulphate, afopic folic acid, albentel albendazole, acetato de dexam …
  • Menasha Corporation:企業の戦略・SWOT・財務分析
    Menasha Corporation - Strategy, SWOT and Corporate Finance Report Summary Menasha Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • The Midcounties Co-operative:企業の戦略・SWOT・財務情報
    The Midcounties Co-operative - Strategy, SWOT and Corporate Finance Report Summary The Midcounties Co-operative - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • National Health Research Institutes:製薬・医療:M&Aディール及び事業提携情報
    Summary National Health Research Institutes (NHRI) is a non-profit foundation that performs medical research programs. The foundation investigates various aspects of basic biomedical sciences and diseases including aging, cancer, infectious diseases, mental disorders and occupational diseases. It co …
  • Repower AG:電力:M&Aディール及び事業提携情報
    Summary Repower AG (Repower), formerly Ratia Energie AG is an energy company that produces, transmits and distributes electricity. The company's services include trading, market access, and sales support services. It generates electric energy from hydropower, wind power plants, and combined-cycle ga …
  • Connected Energy:企業の戦略的SWOT分析
    Connected Energy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • The Tinplate Company of India Limited:企業の戦略・SWOT・財務情報
    The Tinplate Company of India Limited - Strategy, SWOT and Corporate Finance Report Summary The Tinplate Company of India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Satrec Initiative Co., Ltd.:企業の戦略・SWOT・財務分析
    Satrec Initiative Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Satrec Initiative Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Hunt Oil Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Hunt Oil Co (Hunt Oil), a subsidiary Hunt Consolidated, Inc., is an independent upstream company. It carries out exploration, production and development of oil and natural gas. In the US, it has acreage and active programs in the Williston Basin (Bakken) of North Dakota, the Permian Basin of …
  • Citius Pharmaceuticals Inc (CTXR):製薬・医療:M&Aディール及び事業提携情報
    Summary Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Min …
  • Terme Dobrna D.D.
    Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report Summary Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • New Gold Inc:企業の戦略・SWOT・財務情報
    New Gold Inc - Strategy, SWOT and Corporate Finance Report Summary New Gold Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dynavax Technologies Corp (DVAX):企業の財務・戦略的SWOT分析
    Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Rongsheng Petrochemical Co Ltd (002493):企業の財務・戦略的SWOT分析
    Summary Rongsheng Petrochemical Co Ltd (Rongsheng), a subsidiary of Zhejiang Rongsheng Holding Group Co Ltd is a chemical company that produces and distributes PTA, polyester fiber and chemical products. The company’s products include synthetic fibers and films, synthetic raw material, synthetic res …
  • United India Insurance Co Ltd:企業の戦略・SWOT・財務分析
    United India Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary United India Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • SI-Bone Inc (SIBN):医療機器:M&Aディール及び事業提携情報
    Summary SI-Bone Inc (SI-BONE) is a medical device company that develops, manufactures and distributes diagnosing and treating patients with SI joint disorders products and tools. The company offers medical devices for patients with low back issues, degenerative sacroiliitis, and SI joint disruptions …
  • Impresario Entertainment and Hospitality Pvt., Ltd.:企業の戦略・SWOT・財務情報
    Impresario Entertainment and Hospitality Pvt., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Impresario Entertainment and Hospitality Pvt., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • AB Sciex LLC:医療機器:M&Aディール及び事業提携情報
    Summary AB Sciex LLC (Sciex), a subsidiary of Danaher Corp, is a provider of life science analytical technologies. The company provides mass spectrometry solutions combined with capillary electrophoresis and liquid chromatography. Its product portfolio includes liquid chromatography-mass spectromete …
  • Progenics Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Progenics Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Progenics Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Sarah Cannon Research Institute LLC-製薬・医療分野:企業M&A・提携分析
    Summary Sarah Cannon Research Institute LLC (SCRI) is a research institute that offers integrated cancer services. The institute conducts clinical research programs for advancing cancer therapies. Its services include blood cancer network, cancer care overview, cardiovascular research, contract rese …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆